N

    Novavax Inc (NVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.37
    +0.11 (+1.19%)

    Market Cap: $1.53B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    -3.66%
    Streak
    6 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.18
    Range$-0.47 - $0.50
    8 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.02+87.5%
    60d ago$-0.02+87.5%
    30d ago$-0.02+87.5%
    7d ago$-0.02+87.5%
    Current$-0.18
    Revenue Consensus
    $83M
    Range$33M - $179M
    8 analysts
    Dec 31, 2026
    EPS Consensus$0.16
    Range$-0.53 - $1.27
    9 analysts
    Revenue Consensus
    $156M
    Range$45M - $291M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.16---
    Sep 26EST
    		-$-0.18---
    Jun 26
    		$-0.32$-0.36+11.11%Beat-151.6%
    Mar 26
    		$-0.06N/A+83.78%Beat-102.0%
    Dec 25
    		$0.11N/A+116.67%Beat+121.2%
    Sep 25
    		$-0.47N/A+58.41%Beat+38.2%
    Jun 25
    		$0.62$0.06+933.33%Beat-37.4%
    Mar 25
    		$2.93$0.71+312.68%Beat+379.0%
    Dec 24
    		$-0.52$-0.51-1.21%Miss+63.9%
    Sep 24
    		$-0.76$-0.75-1.33%Miss+39.7%
    Jun 24
    		$0.99$1.70-41.76%Miss+70.7%
    Mar 24
    		$-1.05$-1.06+0.94%Beat+69.2%
    Dec 23
    		$-1.44$-0.35-311.43%Miss+36.8%
    Sep 23
    		$-1.26$-2.21+42.99%Beat+41.4%
    Jun 23
    		$0.58$-1.16+150.00%Beat+108.9%
    Mar 23
    		$-3.41$-3.46+1.45%Beat-233.2%
    Dec 22
    		$-2.28$-1.05-117.14%Miss+79.6%
    Sep 22
    		$-2.15$1.59-235.22%Miss+50.1%
    Jun 22
    		$-6.53$5.18-226.06%Miss-37.5%
    Mar 22
    		$2.56$2.65-3.40%Miss+183.9%
    Dec 21
    		$-11.18$-1.80-521.11%Miss-314.1%
    Sep 21
    		$-4.31$-3.55-21.41%Miss-34.3%
    Jun 21
    		$-4.75$-3.25-46.15%Miss-1483.3%
    Mar 21
    		$-3.05$-3.60+15.28%Beat-425.9%
    Dec 20
    		$-2.70$-1.49-81.21%Miss-138.9%
    Sep 20
    		$-3.21$1.73-285.55%Miss-189.2%
    Jun 20
    		$-0.30$-0.33+9.09%Beat+82.2%
    Mar 20
    		$-0.58$-0.67+13.43%Beat+73.6%
    Dec 19
    		$-1.13$-1.06-6.60%Miss+56.5%
    Sep 19
    		$-1.11$-0.89-24.72%Miss+53.8%
    Jun 19
    		$-1.69$-1.59-6.29%Miss+29.6%
    Mar 19
    		$-2.20$-2.26+2.65%Beat+21.4%
    Dec 18
    		$-2.60$-2.60+0.00%Beat+18.8%
    Sep 18
    		$-2.40$-2.52+4.76%Beat+20.0%
    Jun 18
    		$-2.40$-2.46+2.44%Beat+25.0%
    Mar 18
    		$-2.80$-2.78-0.72%Miss+12.5%
    Dec 17
    		$-3.20$-3.09-3.56%Miss+23.8%
    Sep 17
    		$-3.00$-3.19+5.96%Beat+37.5%
    Jun 17
    		$-3.20$-3.17-0.95%Miss-
    Mar 17
    		$-3.20$-3.47+7.78%Beat-
    Dec 16
    		$-4.20$-4.58+8.30%Beat-
    Sep 16
    		$-4.80$-5.24+8.40%Beat-

    Key Metrics

    Valuation
    P/E Ratio-12.66EV/EBITDA1.72x
    Price/FCF-35.84xFCF Yield-2.79%
    Profitability
    Profit Margin-59.90%Operating Margin-89.60%
    ROE-898.00%ROIC489.59%
    Financial Health
    Debt/Equity-1.53xInterest Coverage9.63x
    Current Ratio2.33xQuick Ratio2.30x
    Trading Statistics
    Beta2.42Avg Volume4.63M
    52-Week High$11.9752-Week Low$6.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.93
    SMA 20$8.42
    SMA 50$8.47
    SMA 200$8.49
    EMA 10$8.95
    EMA 20$8.64
    EMA 50$8.55
    EMA 200$8.51

    MACD

    Line: 0.30Signal: 0.15Hist: 0.15

    ADX

    ADX: 27.9+DI: 37.0-DI: 12.2

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down4.0
    PSAR$8.80

    Bollinger Bands

    Upper Band$9.66
    Lower Band$7.18
    %B Position2953%(Upper)
    Band Width0.88

    RSI (14-Day)

    Neutral
    64.3

    Momentum Oscillators

    Stoch %K75.2
    Stoch %D78.6
    Williams %R-28.5
    ROC (10d)16.1%
    Momentum1.30
    CCI (20d)135.9
    MFI (14d)68.6

    Volatility Measures

    ATR (14d)$0.47(5.1%)
    StdDev (20d)0.62
    Hist Vol55.5%(High)

    Volume Flow

    VWAP$9.48
    OBV68.0M
    AD Line-141.6M
    CMF (20d)0.358

    Volume Metrics

    Avg Vol (20d)4.7M
    Vol Ratio1.5x(High)
    VWMA (20d)$8.59

    Pivot Points

    R3$9.89
    R2$9.61
    R1$9.44
    Pivot Point$9.16
    S1$8.99
    S2$8.71
    S3$8.54

    Advanced Oscillators

    TSI20.57
    Ultimate Osc62.1
    KST89.88

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$56.70M$139.51M$147.14M$70.44M$239.24M$666.65M$88.31M$84.51M$415.48M$93.86M$291.34M$186.99M
    Cost of Revenue$14.25M$30.70M$22.10M$21.50M$15.32M$14.12M$36.67M$60.62M$46.24M$59.21M$154.98M$98.93M
    Gross Profit$42.45M$108.82M$125.03M$48.95M$223.91M$652.54M$51.64M$23.89M$369.24M$34.65M$136.37M$88.06M
    Operating Expenses$97.36M$124.25M$110.81M$226.97M$122.84M$137.03M$182.72M$157.91M$208.24M$179.48M$319.93M$213.69M
    R&D$70.69M$95.47M$75.88M$98.27M$79.23M$88.94M$104.38M$87.16M$106.95M$92.68M$164.70M$106.23M
    SG&A$26.66M$28.78M$34.12M$31.66M$43.61M$48.09M$78.34M$70.75M$101.30M$86.80M$155.24M$107.46M
    Operating Income$-54,906,000$-15,430,000$14.23M$-178,018,000$101.07M$515.51M$-131,080,000$-134,018,000$161.00M$-144,831,000$-183,568,000$-125,632,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$5.69M$4.90M$5.82M$34.20M$5.52M$5.72M$7.58M$4.24M$4.14M$4.11M$4.12M$2.86M
    Income Before Tax$-51,676,000$-8,506,000$17.90M$-203,036,000$107.45M$519.85M$-73,581,000$-122,332,000$164.59M$-145,288,000$-176,701,000$-131,473,000
    Income Tax Expense$1.71M$985,000$376,000$-657,000$946,000$1.20M$7.45M$-1,032,000$2.21M$2.26M$1.69M$-697,000
    Net Income$-53,387,000$-9,491,000$17.53M$-202,379,000$106.51M$518.65M$-81,030,000$-121,300,000$162.38M$-147,550,000$-178,389,000$-130,776,000
    EBITDA$-42,931,000$-543,000$28.85M$-162,255,000$120.53M$533.91M$-53,479,000$-105,396,000$179.86M$-129,030,000$-161,790,000$-117,293,000
    EBIT$-45,987,000$-3,605,000$23.73M$-168,840,000$112.97M$525.57M$-65,996,000$-118,096,000$168.73M$-141,177,000$-172,584,000$-128,614,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NVAX

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    100.0%
    Active Awards
    0
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Novavax Q2 results: Revenue beats, 2026 guidance raised to $275M

    Novavax (NASDAQ: NVAX) reported Q2 revenue of $56.7 million, surpassing Wall Street expectations, and raised its full-year 2026 revenue guidance to a range of $235 million-$275 million. The company's shares rose 7% following the announcement, reflecting improved operational efficiency and strong demand visibility. Novavax also highlighted its cash position of $724 million and the potential for a $125 million milestone payment from its Sanofi partnership upon the initiation of a Phase 3 COVID-19-Influenza Combination trial.

    scanx.trade•8/25/26•
    Bullish

    Novavax Stock Rallies Tuesday: What's Happening?

    Novavax (NASDAQ: NVAX) stock is rallying due to renewed investor interest in late-stage vaccine developers, driven by positive clinical trial results from sector peers and the potential of Novavax's Matrix-M adjuvant technology. The company also reported strong second-quarter financial results, raised its full-year 2026 revenue guidance, and is progressing with a co-development partnership with Sanofi that includes a significant milestone payment. These factors, combined with cost-reduction measures, are improving Novavax's financial outlook and attracting buying interest.

    TradingView•8/25/26•
    Bullish

    Novavax Inc. stock outperforms competitors on strong trading day

    Novavax Inc. (NVAX) saw its stock rally 6.55% to $9.44, outperforming major indices like the NASDAQ Composite and the Dow Jones Industrial Average on a strong trading day. The company's stock closed 21.14% below its 52-week high of $11.97, which was reached on February 26th. This performance occurred as the broader market also experienced gains.

    MarketWatch•8/25/26•
    Bullish

    Novavax Inc. stock outperforms competitors on strong trading day

    Novavax Inc. (NVAX) saw its stock price rally by 6.18% to $8.94, outperforming competitors on a positive trading day for the overall stock market. The company's shares closed 25.31% below its 52-week high of $11.97. This strong performance occurred as both the NASDAQ Composite Index and the Dow Jones Industrial Average also rose.

    MarketWatch•8/21/26•
    Bullish

    Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy Rally - Recursion Phar

    Recursion Pharmaceuticals, Novavax, and CRISPR Therapeutics stocks experienced pre-market declines after a recent rally driven by positive Phase 3 results for an individualized mRNA cancer therapy from Merck & Co. and Moderna. Recursion also faced company-specific pressure from a director's plan to sell Class A shares. Despite these pre-market slips, all three stocks had closed significantly higher the previous day.

    Benzinga•8/20/26•
    Neutral

    Frequently Asked Questions About NVAX

    Does NVAX pay dividends?
    Novavax Inc (NVAX) does not currently pay a regular dividend.
    What is NVAX's market cap?
    Novavax Inc (NVAX) has a market capitalization of $1.53B with a current stock price of $9.37.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In